HMOX1 Antibodies

Structure of HMOX1

HMOX1 is a stress-induced protein with a molecular weight of approximately 32.8 kDa. Its precise molecular weight may vary slightly due to different subtypes and post-translational modifications.

This protein is composed of 288 amino acids and forms a unique α -helical folding structure. Its active center contains conserved histidine residues, which can specifically bind to and clet heme molecules. The hydrophobic domain at the C-terminal of the enzyme protein is anchored on the endoplasmic reticulum membrane, while the catalytic domain at the N-terminal is exposed in the cytoplasm. This topological structure enables it to efficiently capture heme substrates in the cytoplasm. The key histidine in the active site coordinates with heme iron, while the adjacent hydrophobic pockets regulate substrate specificity and prevent the decomposition of reaction intermediates.

Fig. 1 Mechanism through which HMOX1 can be regulated.¹

Key structural properties of HMOX1:

• Globular domains consisting mainly of α-helices
• Hydrophobic channel through protein internal direct active center
• Conserved histidine residues are coordinately bound to heme iron

Functions of HMOX1

The main function of HMOX1 is to catalyze the decomposition of heme and participate in cellular defense. In addition, it also involves a variety of physiological and pathological processes, including oxidative stress regulation and cell protection.

This enzymatic reaction follows a unique seven-step catalytic mechanism, which is different from the single-step process of conventional oxidase, demonstrating its dual biological significance of eliminating toxic substances while achieving resource recycling.

Applications of HMOX1 and HMOX1 Antibody in Literature

1. Zheng, Chenyang, et al. "Donafenib and GSK‐J4 synergistically induce ferroptosis in liver cancer by upregulating HMOX1 expression." Advanced Science 10.22 (2023): 2206798. https://doi.org/10.1002/advs.202206798

This study reveals the synergistic anti-liver cancer mechanism of donafenib and GSK-J4: The combination of the two drugs can enhance the enhancer-promoter interaction of the HMOX1 gene, promote its expression and induce ferroptosis, effectively inhibiting tumors.

2. Shi, Juan, et al. "Histone acetyltransferase P300 deficiency promotes ferroptosis of vascular smooth muscle cells by activating the HIF-1α/HMOX1 axis." Molecular Medicine 29.1 (2023): 91. https://doi.org/10.1186/s10020-023-00694-7

This study reveals that P300 affects ferroptosis in vascular smooth muscle cells by regulating the HIF-1α/HMOX1 pathway. P300 can competitively bind to HIF-1α with P53. The decrease in its expression will promote the activation of the HIF-1α/HMOX1 axis, thereby exacerbating ferroptosis.

3. Hamilton, Fergus W., et al. "HMOX1 genetic polymorphisms and outcomes in infectious disease: a systematic review." PLoS One 17.5 (2022): e0267399. https://doi.org/10.1371/journal.pone.0267399

Existing studies have shown that the length of GT(n) repeat sequences in the promoter region of the HMOX1 gene may be associated with the susceptibility and outcomes of various human infectious diseases, but the clinical evidence is still inconsistent and further verification is needed.

4. Hong-Fang Liu, MSce. "Distinct roles of HMOX1 on tumor epithelium and macrophage for regulation of immune microenvironment in ovarian cancer." International Journal of Surgery 111 (2025): 6725-6742. https://doi.org/10.1097/JS9.0000000000002829

Research has found that HMOX1 has a "double-edged sword" effect in ovarian cancer: its expression decreases in tumor epithelial cells but is upregulated in macrophages. Both activate immunosuppressive macrophages through different pathways and weaken anti-tumor immunity.

5. Batra, Neelu, et al. "The HMOX1 Pathway as a Promising Target for the Treatment and Prevention of SARS-CoV-2 of 2019 (COVID-19)." International journal of molecular sciences 21.17 (2020): 6412. https://doi.org/10.3390/ijms21176412

Research has found that the ORF3a protein of the novel coronavirus has a high affinity binding with the HMOX1 protein of the human body. Regulating the HMOX1-ORF3a interaction may provide a new strategy for the treatment of COVID-19 by modulating the innate immune response.

Creative Biolabs: HMOX1 Antibodies for Research

Creative Biolabs specializes in the production of high-quality HMOX1 antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom HMOX1 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our HMOX1 antibodies, custom preparations, or technical support, contact us at email.